6 results on '"Irani, SR"'
Search Results
2. Paraneoplastic neurological syndromes: a practical approach to diagnosis and management.
- Author
-
Binks S, Uy C, Honnorat J, and Irani SR
- Subjects
- Autoantibodies, Humans, Immunotherapy, Paraneoplastic Syndromes, Nervous System diagnosis, Paraneoplastic Syndromes, Nervous System therapy
- Abstract
Paraneoplastic neurological syndromes (PNS) are the immune-mediated effects of a remote cancer and are characterised by an autoantibody response against antigens expressed by the tumour. Classically, well-characterised 'onconeuronal' antibodies target intracellular antigens and hence cannot access their antigens across intact cell membranes. The pathogenic mediators are likely to be neuronal-specific T cells. There is a variable response to immunotherapies and the clinical syndrome helps to direct the search for a specific set of tumours. By contrast, many newly emerging autoantibodies with oncological associations target cell surface epitopes and can exert direct pathogenic effects on both the central and peripheral nervous systems. Patients with these cell-surface directed autoantibodies often clearly respond to immunotherapies. Overall, the clinical, serological and oncological features in an individual patient help to determine the clinical relevance of the syndrome and hence guide its management. We summarise current knowledge and a practical approach to the investigation, diagnosis, treatment and outcomes of patients with suspected PNS., Competing Interests: Competing interests: SRI is a coapplicant and receives royalties on patent application WO/2010/046716 (UK patent number, PCT/GB2009/051441) entitled ‘Neurological Autoimmune Disorders’. The patent has been licensed commercially for the development of assays for LGI1 and other VGKC complex antibodies. SRI and SB are coapplicants on a patent application entitled 'Diagnostic Strategy to Improve Specificity of CASPR2 Antibody Detection' (PCT/GB2019/051257, publication number WO/2019/211633 and UK1807410.4). SRI has received honoraria from UCB, MedImmun, ADC therapeutics and Medlink Neurology, and research support from CSL Behring, UCB and ONO Pharma. CU and JH declare no competing interests with respect to this publication., (© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2022
- Full Text
- View/download PDF
3. Autoimmune encephalitis: clinical spectrum and management.
- Author
-
Uy CE, Binks S, and Irani SR
- Subjects
- Autoantibodies, Humans, Encephalitis diagnosis, Encephalitis therapy, Hashimoto Disease diagnosis, Hashimoto Disease therapy, Movement Disorders
- Abstract
Autoimmune encephalitis defines brain inflammation caused by a misdirected immune response against self-antigens expressed in the central nervous system. It comprises a heterogeneous group of disorders that are at least as common as infectious causes of encephalitis. The rapid and ongoing expansion of this field has been driven by the identification of several pathogenic autoantibodies that cause polysymptomatic neurological and neuropsychiatric diseases. These conditions often show highly distinctive cognitive, seizure and movement disorder phenotypes, making them clinically recognisable. Their early identification and treatment improve patient outcomes, and may aid rapid diagnosis of an underlying associated tumour. Here we summarise the well-known autoantibody-mediated encephalitis syndromes with neuronal cell-surface antigens. We focus on practical aspects of their diagnosis and treatment, offer our clinical experiences of managing such cases and highlight more basic neuroimmunological advances that will inform their future diagnosis and treatments., Competing Interests: Competing interests: SRI is a coapplicant and receives royalties on patent application WO/2010/046716 (U.K. patent no., PCT/GB2009/051441) entitled ‘Neurological Autoimmune Disorders’. The patent has been licensed commercially for the development of assays for LGI1 and other VGKC-complex antibodies. SRI and SB are coapplicants on a patent application entitled ‘Diagnostic Strategy to improve specificity of CASPR2 antibody detection’ (PCT/GB2019/051257, publication number WO/2019/211633 and UK1807410.4). SRI has received honoraria from UCB, MedImmun, ADC therapeutics and Medlink Neurology, and research support from CSL Behring, UCB and ONO Pharma. CU declares no competing interests with respect to this publication., (© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ.)
- Published
- 2021
- Full Text
- View/download PDF
4. Stop testing for autoantibodies to the VGKC-complex: only request LGI1 and CASPR2.
- Author
-
Michael S, Waters P, and Irani SR
- Subjects
- Autoimmune Diseases drug therapy, Autoimmune Diseases immunology, Humans, Intracellular Signaling Peptides and Proteins metabolism, Isaacs Syndrome drug therapy, Autoantibodies immunology, Intracellular Signaling Peptides and Proteins immunology, Limbic Encephalitis drug therapy, Membrane Proteins immunology, Nerve Tissue Proteins immunology, Potassium Channels, Voltage-Gated immunology
- Abstract
Autoantibodies to leucine-rich glioma-inactivated 1 (LGI1) and contactin-associated protein like-2 (CASPR2) are associated with clinically distinctive syndromes that are highly immunotherapy responsive, such as limbic encephalitis, faciobrachial dystonic seizures, Morvan's syndrome and neuromyotonia. These autoantibodies target surface-exposed domains of LGI1 or CASPR2, and appear to be directly pathogenic. In contrast, voltage-gated potassium channel (VGKC) antibodies that lack LGI1 or CASPR2 reactivities ('double-negative') are common in healthy controls and have no consistent associations with distinct syndromes. These antibodies target intracellular epitopes and lack pathogenic potential. Moreover, the clinically important LGI1 and CASPR2 antibodies comprise only ~15% of VGKC-positive results, meaning that most VGKC-antibody positive results mislead rather than help. Further, initial VGKC testing misses some cases that have LGI1 and CASPR2 antibodies. These collective observations confirm that laboratories should stop testing for VGKC antibodies and instead, test only for LGI1 and CASPR2 antibodies. This change in practice will lead to significant patient benefit., Competing Interests: Competing interests: SRI and PW are coinventors on ‘A Diagnostic Strategy to improve specificity of CASPR2 antibody detection.’ Ref. JA94536P. SRI is a co-applicant and receives royalties on patent application WO/2010/046716 (U.K. patent no. PCT/GB2009/051441) entitled ‘Neurological Autoimmune Disorders’. The patent has been licensed for the development of assays for LGI1 and other VGKC-complex antibodies. He has received honoraria from UCB, MedImmune, ADC Therapeutics and MedLink Neurology, and research funding from UCB, ONO and CSL Pharmaceuticals. PW is a named inventor on patents for antibody assays and has received royalties. He has received honoraria from Biogen Idec, Mereo BioPharma, Retrogenix and UBC; travel grants from the Guthy-Jackson Charitable Foundation., (© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ.)
- Published
- 2020
- Full Text
- View/download PDF
5. Organic neuropsychiatry: a treatable cause of suicidal behaviour.
- Author
-
Irani SR, Vincent A, Jacobson L, Logsdail S, and Butterworth RJ
- Subjects
- Adult, Antibodies blood, Autoimmune Diseases of the Nervous System complications, Autoimmune Diseases of the Nervous System therapy, Diagnosis, Differential, Humans, Immunotherapy, Male, Mental Disorders complications, Mental Disorders therapy, Potassium Channels, Voltage-Gated immunology, Autoimmune Diseases of the Nervous System diagnosis, Autoimmune Diseases of the Nervous System psychology, Mental Disorders diagnosis, Mental Disorders psychology, Neuropsychiatry, Suicidal Ideation
- Published
- 2013
- Full Text
- View/download PDF
6. Autoantibody testing in encephalopathies.
- Author
-
Lee R, Buckley C, Irani SR, and Vincent A
- Subjects
- Animals, Humans, Autoantibodies metabolism, Central Nervous System Diseases diagnosis, Central Nervous System Diseases immunology, Central Nervous System Diseases metabolism
- Published
- 2012
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.